SCHEMBL6773157

SCHEMBL6773157

N#Cc1ccc(-c2cccnc2)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 9/20 0.56
CYP11B1 P15538 8/20 0.55
CYP17A1 P05093 2/20 0.55
MEN1 O00255 1/20 0.53
PSIP1 O75475 1/20 0.53
AXL P30530 1/20 0.53
MKNK1 Q9BUB5 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
CYP1A2 P05177 2/20 0.48
ALDH1A1 P00352 2/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2A6 P11509 1/20 0.48
AURKA O14965 1/20 0.48
TTK P33981 1/20 0.48
AURKB Q96GD4 1/20 0.48
INCENP Q9NQS7 1/20 0.48
CYP19A1 P11511 3/20 0.47
KDM4E B2RXH2 3/20 0.46
GAA P10253 2/20 0.46
GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6439562 0.87 CYP11B2 (0.56) CYP11B2CYP11B1CYP17A1MEN1PSIP1
SCHEMBL19128281 0.81 CYP11B2 (0.70) CYP11B2CYP11B1CYP17A1
SCHEMBL3319584 0.81 CYP11B2 (0.56) CYP11B2CYP11B1CYP17A1MEN1PSIP1
SCHEMBL5070146 0.80 MEN1 (0.48) CYP11B2CYP11B1MEN1ALDH1A1CYP3A4
SCHEMBL5318551 0.79 ALDH1A1 (0.52) CYP11B2CYP11B1MEN1ALDH1A1CYP3A4
SCHEMBL30516501 0.79 MKNK1 (0.63) CYP11B2CYP11B1CYP17A1MEN1PSIP1
SCHEMBL77876 0.79 MKNK1 (0.63) CYP11B2CYP11B1CYP17A1MEN1PSIP1
SCHEMBL17539135 0.79 CYP11B2 (0.50) CYP11B2CYP11B1CYP17A1MEN1PSIP1
SCHEMBL7813267 0.79 CYP11B2 (0.66) CYP11B2CYP11B1CYP17A1MEN1PSIP1
SCHEMBL1975188 0.78 CYP11B2 (0.43) CYP11B2CYP11B1CYP17A1MEN1PSIP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696475-B2 N-PHENYL-N'-(2-CARBOXYPHENYL) UREA, FOR EXAMPLE; CHLORIDE CHANNEL BLOCKERS; SUCH AS FOR TREATING BONE METABOLIC DISORDERS NEUROSEARCH A/S (DK) 2004-02-24 US disclosed
EP-0977741-B1 SUBSTITUTED PHENYL DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH AS (DK) 2003-09-03 EP disclosed
US-20020037905-A1 Substituted phenyl derivatives, their preparation and use ANIONA APS (DK) 2002-03-28 US disclosed
US-6297261-B1 POTENT CHLORIDE CHANNEL BLOCKERS; TREATMENT OF SICKLE CELL ANEMIA, BRAIN EDEMA FOLLOWING ISCHAEMIA OR TUMORS, DIARRHEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, AND FOR THE REDUCTION OF THE INTRAOCULAR PRESSURE NEUROSEARCH A/S (DK) 2001-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037905-A1 Substituted phenyl derivatives, their preparation and use KCNB1, KCNH2, KCNJ2 CYP11B2 347/4885CYP11B1 341/4885CYP17A1 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.